NVSEF - Aerovate: Imatinib Delivery Change Leads To Targeting Of Massive PAH Market
2024-06-11 13:19:13 ET
Summary
- Aerovate Therapeutics, Inc. results from the phase 2 portion of the phase 3 IMPAHCT trial, using AV-101 for the treatment of patients with pulmonary arterial hypertension, expected in June 2024.
- The global Pulmonary Arterial Hypertension market size is expected to reach $12.2 billion by 2032.
- Aerovate has been able to take what was achieved with oral Imatinib and convert it to a dry inhaled powder that can be used to treat pulmonary arterial hypertension.
- AV-101 can become standard of care for PAH, when added to background therapy for PAH patients, if it can be shown to be superior to Merck's Winrevair.
Aerovate Therapeutics, Inc. ( AVTE ) is developing a drug known as AV-101, which is being used to treat patients with pulmonary arterial hypertension [PAH]. The use of this inhaled drug is being explored in the ongoing phase 2b/3 IMPAHCT trial. Speaking of inhaled drug, this is highly promising. The reason why I say that is because AV-101 is an inhaled version of imatinib. It had done well in clinical trial when given to patients orally, but the problem was systemic side effects....
Aerovate: Imatinib Delivery Change Leads To Targeting Of Massive PAH Market